​

TRAUMATIC BRAIN INJURY COMPANION : TBICheck™

 

3 MILLION PATIENT ARE ADMITTED TO HOSPITAL EVERY YEAR FOR CT-SCAN

                 TO CHECK FOR BRAIN LESIONS

                                       AND 90% OF THEM ARE NEGATIVE !

 

                      

                    THE PROCESS OF A CT-SCAN CAN TAKE UP TO 6 HOURS

 

SPEED UP THE DIAGNOSTIC AND DECISION

           PROCESSES FROM 6 HOURS TO

                          15 MINUTES

 

              

                       

                                  

​

 

A PORTABLE DEVICE TO DETECT MILD TRAUMATIC INJURIES

​

Traumatic brain injury (TBI) is the leading cause of death and disability in young adults. The incidence in elderly patients is increasing. In younger patients, Road Traffic Accidents are the most frequent cause of injury, while in older patients it is falls. Sports, army and juveniles are vulnerable collectives.

In particular, mild traumatic brain injury (mTBI) is responsible for high health costs. In contrast to severe TBI, brain lesions are not easily detectable in mTBI-affected patients. Current practice is to perform a CT-scan where available, to determine presence of brain lesions. However, CT-scan is expensive, can only be carried out in appropriately equipped facilities and carries some risk and radiation exposure to the patient. Generally, only a small proportion (6-8%) of patients will have confirmation of a brain injury requiring hospital stay, while more than 90% of the patients are dismissed after the CT-scan.

TBIcheck™ allows to rule out the presence of brain injury with a simple blood test from a finger prick. So the unnecessary CT-scan can be avoided in one third of the patients, reducing the costs for healthcare systems, as well as reducing stress, inconvenience and radiation exposure to patients and relieving burden on over-stressed emergency departments. Moreover, TBIcheck™ opens the way to the future immediate diagnosis on the site where the accident occurred, avoiding the transportation to the hospital, especially for accidents occurring in remote locations.

​

​

• 1. Detection of mild Traumatic Brain Injury

• 2. Differentiation between ischemic and hemorrhagic stroke

• 3. Earlier identification of risk of post-stroke infection and other complications

​

​

​

​

​

​

​

​

​

​

 

 

 

 

 

​

​​​​​INTELLECTUAL PROPERTY (IP) STATUS

​

ABCDx secured exclusive commercial rights to a cluster of patent applications protecting the use of multiple-parametric tests for patients presenting with symptoms of head injury. This IP places ABCDx as the leading company offering new approaches assessing clinical decisions and rapidly selecting therapeutic intervention, even in decentralised locations.

Markers and their use in Brain Injury (WO2016/055148)

​

RELEVANT SCIENTIFIC PUBLICATIONS

​

Lagerstedt L, Egea-Guerrero JJ, Bustamante A, Rodríguez-Rodríguez A, El Rahal A, Quintana-Diaz M, et al. (2018) Combining H-FABP and GFAP increases the capacity to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury. PLoS ONE 13(7): e0200394. https://doi.org/10.1371/journal.pone.0200394

Lagerstedt L, Egea-Guerrero JJ, Bustamante A, Montaner J, Rodríguez-Rodríguez A, El Rahal A, et al. (2017) H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury. PLoS ONE 12(4): e0175572. https://doi.org/10.1371/journal.pone.0175572